List of Jakafi drug patents

Jakafi is owned by Incyte Corp.

Jakafi contains Ruxolitinib Phosphate.

Jakafi has a total of 16 drug patents out of which 0 drug patents have expired.

Jakafi was authorised for market use on 16 November, 2011.

Jakafi is available in tablet;oral dosage forms.

Jakafi can be used as for treatment of chronic graft-versus-host disease (cgvhd) after failure of one or two lines of systemic therapy; for treatment of steroid-refractory acute graft-versus-host disease (agvhd), for treatment of chronic graft-versus-host disease (cgvhd) after failure of one or two lines of systemic therapy; for treatment of polycythemia vera (pv) in patients who have had an inadequate response to or are intolerant of hydroxyurea; for treatment of intermediate or high-risk myelofibrosis (mf), including primary mf, post-polycythemia vera mf and post-essential thrombocythemia mf; for treatment of steroid-refractory acute graft-versus-host disease (agvhd), for treatment of polycythemia vera (pv) in patients who have had an inadequate response to or are intolerant of hydroxyurea; for treatment of intermediate or high-risk myelofibrosis (mf), including primary mf, post-polycythemia vera mf and post-essential thrombocythemia mf, for treatment of steroid-refractory acute graft-versus-host disease (agvhd); for treatment of chronic graft-versus-host disease (cgvhd) after failure of one or two lines of systemic therapy; for treatment of steroid-refractory acute graft-versus-host disease (agvhd); for treatment of polycythemia vera (pv) in patients who have had an inadequate response to or are intolerant of hydroxyurea; for treatment of polycythemia vera (pv) in patients who have had an inadequate response to or are intolerant of hydroxyurea; for treatment of polycythemia vera (pv) in patients who have had an inadequate response to or are intolerant of hydroxyurea; use of ruxolitinib (jakafi) for inhibiting janus associated kinases (jaks) jak1 and/or jak2.; for treatment of chronic graft-versus-host disease (cgvhd) after failure of one or two lines of systemic therapy; for treatment of chronic graft-versus-host disease (cgvhd) after failure of one or two lines of systemic therapy; for treatment of steroid-refractory acute graft-versus-host disease (agvhd); use of ruxolitinib (jakafi) for inhibiting janus associated kinases (jaks) jak1 and/or jak2.; for treatment of intermediate or high-risk myelofibrosis (mf), including primary mf, post-polycythemia vera mf and post-essential thrombocythemia mf; use of ruxolitinib (jakafi) for inhibiting janus associated kinases (jaks) jak1 and/or jak2.; for treatment of intermediate or high-risk myelofibrosis (mf), including primary mf, post-polycythemia vera mf and post-essential thrombocythemia mf; for treatment of intermediate or high-risk myelofibrosis (mf), including primary mf, post-polycythemia vera mf and post-essential thrombocythemia mf; for treatment of intermediate or high-risk myelofibrosis (mf), including primary mf, post-polycythemia vera mf and post-essential thrombocythemia mf; for treatment of polycythemia vera (pv) in patients who have had an inadequate response to or are intolerant of hydroxyurea; for treatment of intermediate or high-risk myelofibrosis (mf), including primary mf, post-polycythemia vera mf and post-essential thrombocythemia mf; use of ruxolitinib (jakafi) for inhibiting janus associated kinases (jaks) jak1 and/or jak2.; for treatment of chronic graft-versus-host disease (cgvhd) after failure of one or two lines of systemic therapy, for the treatment of polycythemia vera; for the treatment of intermediate or high-risk myelofibrosis; for treatment of intermediate or high-risk myelofibrosis (mf), including primary mf, post-polycythemia vera mf and post-essential thrombocythemia mf; for treatment of polycythemia vera (pv) in patients who have had an inadequate response to or are intolerant of hydroxyurea.

The generics of Jakafi are possible to be released after 12 December, 2028.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7598257 INCYTE CORP Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
Dec, 2027

(4 years from now)

US8415362 INCYTE CORP Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
Dec, 2027

(4 years from now)

US8722693 INCYTE CORP Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9079912 INCYTE CORP Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors
Dec, 2026

(3 years from now)

US9814722 INCYTE CORP Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors
Dec, 2026

(3 years from now)

US9814722

(Pediatric)

INCYTE CORP Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors
Jun, 2027

(4 years from now)

US9079912

(Pediatric)

INCYTE CORP Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors
Jun, 2027

(4 years from now)

US8829013 INCYTE CORP Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

US10016429 INCYTE CORP Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

US8822481 INCYTE CORP Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

US8415362

(Pediatric)

INCYTE CORP Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
Jun, 2028

(5 years from now)

US7598257

(Pediatric)

INCYTE CORP Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
Jun, 2028

(5 years from now)

US8722693

(Pediatric)

INCYTE CORP Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Dec, 2028

(5 years from now)

US8822481

(Pediatric)

INCYTE CORP Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Dec, 2028

(5 years from now)

US8829013

(Pediatric)

INCYTE CORP Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Dec, 2028

(5 years from now)

US10016429

(Pediatric)

INCYTE CORP Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Dec, 2028

(5 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Sep 22, 2024
Orphan Drug Exclusivity (ODE) Sep 22, 2028
Pediatric Exclusivity (PED) Nov 24, 2026

Drugs and Companies using RUXOLITINIB PHOSPHATE ingredient

Market Authorisation Date: 16 November, 2011

Treatment: For treatment of chronic graft-versus-host disease (cgvhd) after failure of one or two lines of systemic therapy; For treatment of polycythemia vera (pv) in patients who have had an inadequate response to or are intolerant of hydroxyurea; For treatment of intermediate or high-risk myelofibrosis (mf), including primary mf, post-polycythemia vera mf and post-essential thrombocythemia mf; For treatment of steroid-refractory acute graft-versus-host disease (agvhd); For the treatment of polycythemia vera; For the treatment of intermediate or high-risk myelofibrosis; Use of ruxolitinib (jakafi) for inhibiting janus associated kinases (jaks) jak1 and/or jak2.

Dosage: TABLET;ORAL

How can I launch a generic of JAKAFI before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in